集團簡介
愛爾眼科創立于 2002 年，醫療網絡布局亞洲、歐洲和北美洲，于 2009 年在中國深圳上市（股票代碼：300015）；公司在歐洲、東南亞的分支機構分別在西班牙馬德里（CBAV.MC）、新加坡（SGX:40T）上市。截至 2023 年 12 月 31 日，愛爾眼科品牌醫院、眼科中心及診所在全球范圍內共有 881 家。其中，中國內地 750家（包括上市公司旗下 439 家，產業并購基金旗下 311 家），中國香港 8 家，在海外布局突破 123 家眼科診所， 包括美國 1 家，歐洲 108 家，東南亞 14 家。
Aier Eye Hospital, established in 2002, has
a vast medical presence in Asia, Europe, and North America. Aier Eye Hospital
was listed in 2009 in Shenzhen, China (Stock code: 300015), and its branches in
Europe and Southeast Asia were listed in Madrid, Spain (CBAV.MC) and Singapore
(SGX:40T), respectively. As of December 31, 2023, there were 881 eye hospitals,
eye centers and clinics under Aier brand. Among them, there were 750 in the
Chinese Mainland (including 439 under the Company and 311 under M&A Funds),
8 in Hong Kong, China, and more than 123 located overseas, including 1 in the
United States, 108 in Europe, and 14 in Southeast Asia.
作為全球化眼科醫療集團，愛爾眼科現階段堅持以國內醫療發展為主線，國內國際雙線并舉，共同進步的戰略方針，引進和吸收國際同步的眼科技術與醫療管理理念，以專業化、規模化、科學化的模式助推中國眼科行業的發展，力爭提升中國眼科醫療的整體水平，輻射全球。通過不斷實踐，在引進吸收國際先進的醫療管理經驗的基礎上，愛爾眼科成功探索出了一套適應中國國情和市場環境的眼科醫院連鎖經營管理模式——“分級連鎖”，促進核心醫療資源的高效利用，有效對接國家醫改政策“分級診療、雙向轉診”，真正使老百姓享受到優質、可及的醫療資源。
Domestic market is the core business of
AIER and international market plays a more and more important role in our
global strategy. We are committed to introducing and absorbing the cutting-edge
technology and advanced management concepts, as well as to contributing to the
evolution of China's ophthalmology market, in a specialized, scaled-up and
scientific way.
AIER has successfully explored the business
model in line with China’s national and market condition through continuous
practice- the “hierarchical chain”- to fully utilize advantages in talent,
technology and management so as to achieve better clinical outcome, to improve service
standard and to optimize communication between patients and medical personnel.
科研創新、人才培養是長遠發展的基石，愛爾眼科不斷加大科研投入，大力支持開展前沿性、原創性的眼科學術研究，全力推進全球化平臺上的眼健康生態圈戰略。自2013年與中南大學聯合成立中南大學愛爾眼科學院，正式開啟校企合作的創新探索以來，愛爾眼科已陸續推動了與多家國內外知名高校的戰略合作，充分發揮企業和高校的獨特優勢，在醫院共建、人才培養、師資隊伍建設、教學科研等領域展開深入合作，聯手共建頂尖眼科醫教研平臺，為社會培養更多優秀的眼科醫學人才，真正地為中國眼科學和視覺科學的創新發展貢獻智慧與力量。
Scientific research innovation and talent cultivation are the cornerstones of long-term development. We vigorously support the development of original and cutting-edge scientific research and make ourselves committed to creating a closed-loop ophthalmic ecosystem on a global platform by gradually increasing investment.
Since the joint establishment of AIER School of Ophthalmology of Central South University by AIER and Central South University in 2013, an innovative exploration of school-enterprise cooperation was officially launched. AIER then successively promoted strategic cooperation with well-known universities, such as Hubei University of Science and Technology, Wuhan University, Jinan University, Anhui Medical University, Tianjin University, and Sichuan University, etc.
AIER and the universities are sharing the
same goal to build an integrated education and research platform by leveraging
the strengths of “Good Company” and “Famous University” through in-depth
collaboration in areas of hospital co-management, talent and faculty training,
academic development and scientific research, so as to train excellent
ophthalmic talents for the community, as well as to contribute our wisdom and
power to the evolution of the ophthalmology and vision science in China.
在此基礎上，愛爾眼科持續打造立體化科研平臺，截止目前已在全國范圍內構建起“八所、二站、二基地、三中心”的創新型科教研一體化平臺。“八所”：愛爾眼科研究所、愛爾眼視光研究所、愛爾角膜病研究所、愛爾屈光研究所、愛爾視網膜研究所、愛爾青光眼研究所、愛爾白內障與人工晶狀體研究所、武漢愛爾眼科研究所。獲批設立“二站”：國家博士后科研工作站、院士專家工作站；“二基地”：眼視光國際科技合作基地、“海智計劃”工作基地；“三中心”：眼視光工程技術研究中心、眼表疾病臨床醫學研究中心、企業技術中心；聯合共建“愛爾眼科-中科院計算所數字眼科聯合實驗室”等創新平臺。
Based on this, AIER continued to create a comprehensive scientific research platform. Up to now, an innovative platform integrating science, education and research. “Eight Institutes, Two Stations, Two Bases, and Three Centers” has been established nationwide.
“Eight Institutes” refers to Eye Institute,
Optometry & Visual Science Institute, Keratoconus Institute, Refractive
Institute, Retina Institute, Glaucoma Institute, Cataract Institute, and AIER
Ophthalmic Research Institute in Wuhan; “Two Stations” refers to National
Post-Doctorates R&D Workstation and Academician Expert Hunan Provincial
Workstation, which was established after approval; “Two Bases” refers to Hunan
International Optometry Science and Technology Cooperation Base and HOME
Program work base in Hunan Province; “Three Centers” refers to Hunan Optometry
Engineering Technology Research Center, Hunan Ocular Surface Disease Clinical
Medicine Research Center, and Hunan Enterprise Technology Center; meanwhile
various innovative platforms such as “AIER-ICT Digital Ophthalmology Joint
Laboratory” were jointly established.
上市十年之際，愛爾眼科以“創新驅動，科技愛爾”為指導方針，提出三大戰略目標。一是要將眼科醫療服務網絡覆蓋到中國的廣大城鄉縣域，讓老百姓在家門口就能享受到高質量的、可及的眼科醫療服務，助推健康中國戰略。二是通過打造世界級及國家級的眼科醫學中心，切實提高中國眼科醫療技術水平，趕超世界先進水平。三是通過全球化布局，醫、教、研、產、投全面協同發展，推動人類眼科學與視覺科學進步。
On the 10th Anniversary of listing, AIER
took “Innovation Driven and Technology Empowered” as the guideline and proposed
three strategic goals. The first goal is to expand the medical service network
into vast urban and rural areas, enabling patients to experience convenient and
high-quality ophthalmic medical service, implementing the strategy of “Healthy
China”. The second goal is to continuously improve ophthalmic medical
technology in China and to be recognized as world-level excellence by building
up world-class and national-level ophthalmic medical center. The last but not
the least goal is to promote advancement of human ophthalmology and visual
science through global footprint as well as coordinated development of
medicine, education, research, industrial and investment.
在二十年的創業發展歷程中，愛爾眼科凝聚和培養了一批經驗豐富、具有開拓創新精神的管理團隊和醫術精良、治學嚴謹的眼科專家和醫生團隊。截至目前，愛爾眼科醫院集團及旗下全球員工總數達50,000余人，其中眼科醫生及視光師總數(含海外) 7,100余人，包括一大批博士生導師、碩士生導師、博士、博士后、留學歐美的學者以及臨床經驗豐富的核心專家。
Through the past 20-year growth and
expansion, AIER has attracted and cultivated a group of experienced management
team with innovative spirit, as well as a team of well-trained ophthalmologists
and doctors with excellent medical skills and rigorous scholarship. At present,
AIER has more than 50,000 employees worldwide. Among them, 7,100 are
ophthalmologists and optometrists (including domestic and overseas), with a big
group of doctoral supervisors, master supervisors, doctors, post-doctors,
oversea scholars, and even core experts with extensive clinical experiences.
愛爾眼科的發展壯大始終“以愛心致力于人類的眼健康”為初心，以“使所有人，無論貧窮富裕，都享有眼健康的權利”為使命，堅持“以患者為中心”，追求社會責任和自身發展的和諧統一。通過開創性的“交叉補貼”模式，在為患者提供更高品質的眼科醫療服務的同時，全面開展防盲治盲工作、投身社會公益、幫助弱勢群體，積極聯合社會各界力量，推動中國防盲事業乃至國民眼健康事業的全面發展。2018年、2020年蟬聯第十屆、第十一屆中國政府最高慈善獎項“中華慈善獎”、榮獲中國公益年會“中國公益企業獎”、“最佳社會責任上市公司”、“湖南慈善獎”等榮譽。同時積極響應國家號召，作為中國代表企業牽頭參與“一帶一路光明行”、“湄公河光明行”等公益活動，獲得組織者、受援國政府和患者的高度好評，逐步發展成為全球慈善公益活動的一張名片。
The growth of AIER always sticks to the
original intention and mission of “Enabling everyone, no matter rich or poor,
has the right to eye health”. We are committed to the bright future of all
human beings, insisting on “patient-oriented” principle, and pursuing the
harmonious unity of social responsibility and self-development. By adopting the
pioneering “Cross Subsidy Model”, while offering our patients higher-quality
ophthalmic medical service, AIER also comprehensively carries out blindness
prevention and treatment, devotes to public welfare, helps vulnerable groups,
and actively unites all forces from society, promoting the comprehensive
development of China’s blindness prevention and even the eye health career of
citizens. In 2018 and 2020, AIER was awarded the 10th and the 11th “China
Charity Award” by Chinese Government. Besides, we were also awarded many other
honors, such as “China Public Welfare Enterprise Award”, “Best Socially
Responsible Public Company”, and “Hunan Charity Award”, etc. Moreover, AIER
responded positively to the national appeal and took the lead in different
public benefit activities such as “The Belt and Road Brightness Campaign” and
“Mekong Brightness Campaign”, winning unanimous praise from organizers, aid
recipient governments and patients. In this way, AIER has been gradually regarded
as a representative of global philanthropy activities.
愛爾眼科連續多年被權威機構評為“中國最受投資者尊重的上市公司前十強”，蟬聯中國品牌節“華譜獎”，榮獲“最佳持續投資價值獎”、“中國上市公司最佳股東回報獎”、“中國上市公司實業貢獻大獎”等多項殊榮，成功入選滬深300指數股、MSCI中國大盤指數成份股等。
AIER has been rated as “Top 10 Most Valued
Public Company in China” by authoritative institutions for multiple consecutive
years. We won the “China Spectrum Award” of China Brand Festival consecutively
and many other honors, including “Best Sustainable Investment Value Award”,
“Chinese Public Company Best Shareholder Return Award”, and “Chinese Public
Company Industrial Contribution Award”, etc. At the same time, AIER was also
successfully selected as CSI 300 Index Stock and MSCI China Index Constituent
Stock, etc.